Trial reportJournal of cardiothoracic surgery2025
Predictive factors and pharmacological preventive interventions for atrial fibrillation after aortic valve replacement.
Trial report in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the predictive factors for postoperative atrial fibrillation (POAF) following aortic valve replacement (AVR) and evaluate the preventive effect of combined atorvastatin and metoprolol therapy on POAF.
methodsThis study employed a mixed design of retrospective cohort analysis and prospective randomized controlled trial, including 268 patients who underwent isolated AVR from January 1, 2022, to March 31, 2024. The 168 patients from January 1, 2022, to May 31, 2023, were analyzed for POAF predictive factors, while 100 patients from June 1, 2023, were included in the prospective trial. The intervention group (n = 50) received combined atorvastatin and metoprolol treatment starting 7 days before surgery.
resultsMultivariate logistic regression analysis identified age (OR = 1.12, 95% CI: 1.04–1.20, p = 0.003), history of stroke (OR = 10.94, 95% CI: 1.32–90.66, p = 0.027), EuroSCORE II (OR = 2.90, 95% CI: 1.61–5.20, p < 0.001), NT-proBNP level (OR = 1.002, 95% CI: 1.001–1.004, p = 0.009), hs-CRP level (OR = 1.55, 95% CI: 1.16–2.07, p = 0.003), and operation time (OR = 1.02, 95% CI: 1.01–1.04, p = 0.008) as independent predictors of POAF. Pharmacological intervention significantly reduced POAF incidence (p = 0.005) and shortened hospital stay (p < 0.001), ICU stay (p = 0.002), and mechanical ventilation time (p < 0.001). The AUC of the predictive model was 0.952, with a calibrated C-statistic of 0.904. Decision curve analysis demonstrated significant clinical utility across multiple risk thresholds.
conclusionAge, history of stroke, EuroSCORE II, NT-proBNP and hs-CRP levels, and operation time are independent predictors of POAF. Combined preventive treatment with atorvastatin and metoprolol reduced POAF incidence and postoperative hospital stay, showing promising clinical application prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.